

**UPSHER-SMITH**

Partners in Health Since 1919

**Contact:** Elizabeth Likly  
Kovak-Likly Communications  
203-762-8833, elikly@klcpr.com

**FOR IMMEDIATE RELEASE**

**UPSHER-SMITH LAUNCHES  
DOXAZOSIN TABLETS, USP**

Maple Grove, MN – May 1, 2018 – [Upsher-Smith Laboratories, LLC](#) (Upsher-Smith) today announced the launch of Doxazosin Tablets, USP, 1 mg, 2 mg, 4 mg and 8 mg. The product was approved by the U.S. Food and Drug Administration (FDA) on April 17, 2018. Upsher-Smith's Doxazosin Tablets are an AB-rated generic version of the branded product, Cardura® (doxazosin mesylate tablets).\*

The doxazosin tablet market had U.S. sales of approximately \$51.2 million for the 12 months ending January, 2018 according to IQVIA.

**Product Information**

Product	Active Ingredient	Strength	NDC #	Package Size
Doxazosin Tablets, USP	Doxazosin mesylate	1 mg	0832-0356-11	100 ct bottle
Doxazosin Tablets, USP	Doxazosin mesylate	2 mg	0832-0357-11	100 ct bottle
Doxazosin Tablets, USP	Doxazosin mesylate	4 mg	0832-0359-11	100 ct bottle
Doxazosin Tablets, USP	Doxazosin mesylate	8 mg	0832-0358-11	100 ct bottle

For questions about ordering, please call Upsher-Smith at 1-800-654-2299.

**Please refer to the full Prescribing Information for Doxazosin Tablets, USP at [www.upsher-smith.com](http://www.upsher-smith.com). You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information.**

You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting <http://www.fda.gov/medwatch>.

**About Upsher-Smith**

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that has strived to deliver quality, affordable generic medications for nearly a century. In June 2017,

Upsher-Smith was acquired by Sawai Pharmaceutical Co., Ltd., a large publicly traded generics company in Japan that had been seeking entry into the U.S. market. Upsher-Smith and Sawai share a strikingly similar family history and hold many of the same cherished goals and values—most importantly, the philosophy of always putting patients first. Upsher-Smith will continue to do those things it does best, which is provide a consistent supply of quality, affordable medications and invest in its historically strong industry relationships. Ultimately, Upsher-Smith believes the acquisition by Sawai represents a tremendous opportunity to leverage each company for growth worldwide and embark together on an exciting new chapter in generics. For more information, visit [www.upsher-smith.com](http://www.upsher-smith.com).

\* Cardura is a registered trademark of Pfizer Inc.

113231.01

# # #